Neisseria Meningitidis Factor H Binding Protein

Summary

Neisseria Meningitidis Factor H Binding Protein (CHEMBL6068499) is an approved vaccine component; indicated across 3 conditions including infectious meningitis and meningococcal meningitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 3 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068499
Name	Neisseria Meningitidis Factor H Binding Protein
Type	Vaccine component
Max phase	4

Also known as: Trumenba

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
infectious meningitis	4	MONDO:0004796	EFO:0000584
meningococcal meningitis	4	MONDO:0018059	EFO:1001040

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07197762	PHASE4	RECRUITING	MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
NCT04893811	PHASE4	COMPLETED	Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
NCT04440163	PHASE3	COMPLETED	MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
NCT05873751	Not specified	COMPLETED	A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).